Secondary outcome measures included modified Rankin score (mRS) at 3 and 12 months, modified Barthel index (MBI) at 3 and 12 months, mortality at 3 and 12 months, composite negative outcome (death or MBI ≤ 14 or mRS > 2) at 3 and 12 months, and rate of post-stroke infection.
Technical methods, materials, medical history, adverse events and clinical outcome measures, including modified Rankin scale and EQ-5D, will be assessed at several time points.
The primary outcome measures included Modified Barthel Index score, Mini-Mental Status Examination score, and the institutionalization rate.
The use of incentives requires ongoing adjustments to the program including modifying goals that lead to new measures and targets, adding or retiring measures once performance has topped out, adjusting targets for existing measures, and modifying the reward structure.
Primary outcome measures included recanalization rate and modified Rankin Scale score at followup.
Primary outcome measures included recanalization rate and modified Rank in Scale score at followup.
Secondary efficacy measures included the Alzheimer's Disease Cooperative Study Activities of Daily Living Inventory modified for severe dementia (ADCS-ADLsev) and the Neuropsychiatric Inventory (NPI) to measure impact on behavior.
Pre and post intervention measures included Berg Balance Scale, Limits of Stability (LOS) and modified Clinical Test of Sensory Interaction on Balance (mCTSIB).
Measures included insulin resistance and sensitivity (homeostasis model assessment of insulin resistance [HOMA-IR], modified Matsuda Index, 1/fasting insulin) and β-cell function (oral disposition index = [Δinsulin0 30/Δglucose0 30] × [1/fasting insulin]).
Quantitative effectiveness measures included the number of positions/organizations and associated relationships physically or verbally added to the diagram and/or modified by interviewees.
